UroGen Pharma (NASDAQ:URGN) Rating Lowered to “Neutral” at HC Wainwright

UroGen Pharma (NASDAQ:URGN) was downgraded by equities research analysts at HC Wainwright from a “buy” rating to a “neutral” rating in a research report issued to clients and investors on Thursday, Marketbeat Ratings reports.

A number of other brokerages have also recently weighed in on URGN. The Goldman Sachs Group reduced their price target on shares of UroGen Pharma from $22.00 to $16.00 and set a “neutral” rating on the stock in a research report on Thursday, April 17th. LADENBURG THALM/SH SH assumed coverage on shares of UroGen Pharma in a report on Wednesday, February 19th. They set a “buy” rating and a $31.00 target price on the stock. Scotiabank started coverage on shares of UroGen Pharma in a research report on Wednesday, April 16th. They set a “sector outperform” rating and a $23.00 price target for the company. Guggenheim reissued a “buy” rating on shares of UroGen Pharma in a research report on Tuesday, April 29th. Finally, D. Boral Capital reaffirmed a “buy” rating and issued a $25.00 target price on shares of UroGen Pharma in a research report on Thursday, May 8th. Two analysts have rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $31.00.

UroGen Pharma Price Performance

Shares of UroGen Pharma stock opened at $4.08 on Thursday. The business’s fifty day moving average price is $10.18 and its 200 day moving average price is $10.73. UroGen Pharma has a twelve month low of $3.42 and a twelve month high of $20.70. The company has a current ratio of 9.00, a quick ratio of 8.77 and a debt-to-equity ratio of 4.77. The stock has a market capitalization of $188.12 million, a P/E ratio of -1.30 and a beta of 0.66.

UroGen Pharma (NASDAQ:URGN) last released its quarterly earnings data on Monday, May 12th. The company reported ($0.92) earnings per share for the quarter, missing the consensus estimate of ($0.83) by ($0.09). The firm had revenue of $20.25 million during the quarter, compared to analyst estimates of $22.71 million. As a group, research analysts anticipate that UroGen Pharma will post -3.12 earnings per share for the current year.

Institutional Investors Weigh In On UroGen Pharma

A number of large investors have recently added to or reduced their stakes in the company. CWM LLC boosted its position in UroGen Pharma by 6,047.1% in the 1st quarter. CWM LLC now owns 5,225 shares of the company’s stock valued at $58,000 after buying an additional 5,140 shares during the last quarter. KLP Kapitalforvaltning AS acquired a new stake in UroGen Pharma during the 4th quarter valued at approximately $59,000. Lazard Asset Management LLC purchased a new stake in UroGen Pharma during the 4th quarter worth approximately $67,000. GAMMA Investing LLC raised its position in shares of UroGen Pharma by 6,908.4% in the 1st quarter. GAMMA Investing LLC now owns 7,499 shares of the company’s stock valued at $83,000 after purchasing an additional 7,392 shares in the last quarter. Finally, Aquatic Capital Management LLC acquired a new position in shares of UroGen Pharma in the 4th quarter valued at approximately $101,000. 91.29% of the stock is owned by institutional investors and hedge funds.

UroGen Pharma Company Profile

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.